Key facts
- This page summarizes R. Michael Carruthers's Form 4 filing for Elevation Oncology, Inc. (ELEV).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Jun 2023, 16:11.
R. Michael Carruthers - 16 Jun 2023 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)
- Form type
- 4
- Accepted by SEC
- 21 Jun 2023, 16:11:11 UTC
- Previous filing
- 03 May 2023
- Next filing
- 26 Jun 2023
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Robert Yang, Attorney-in-Fact
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
R. Michael Carruthers filed Form 4 for Elevation Oncology, Inc. (ELEV) on 21 Jun 2023.
Change
- Previous filing in this sequence was filed on 03 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELEV
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +31,238
- Change %
- Price
- $0.000000
- Shares after
- 31,238
- Date
- 16 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 31,238
- Exercise price
- $1.47
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
SEC remarks
Exhibit 24 - Power of Attorney